Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Vita 34 stock

V3V.DE
DE000A0BL849
A0BL84

Price

4.16
Today +/-
-0.02
Today %
-0.48 %

Vita 34 stock price

%
Weekly
Details

Price

Overview

The Quote Chart provides detailed and dynamic insights into the Vita 34 stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vita 34 stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vita 34 stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vita 34's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vita 34 Stock Price History

DateVita 34 Price
2/24/20254.16 undefined
2/21/20254.18 undefined
2/20/20254.16 undefined
2/19/20254.18 undefined
2/18/20254.08 undefined
2/17/20254.08 undefined
2/14/20254.16 undefined
2/13/20254.10 undefined
2/12/20254.08 undefined
2/11/20254.10 undefined
2/10/20254.08 undefined
2/7/20254.14 undefined
2/6/20254.06 undefined
2/5/20254.06 undefined
2/4/20254.06 undefined
2/3/20254.06 undefined
1/31/20254.12 undefined
1/30/20254.06 undefined
1/29/20254.06 undefined
1/28/20254.08 undefined
1/27/20254.06 undefined

Vita 34 Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

Understanding Revenue, EBIT, and Income

Gain insights into Vita 34, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vita 34 from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vita 34’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vita 34. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vita 34’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vita 34’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vita 34’s growth potential.

Vita 34 Revenue, EBIT and net profit per share

DateVita 34 RevenueVita 34 EBITVita 34 Net Income
2027e128.03 M undefined921,464.26 undefined0 undefined
2026e87.87 M undefined1.72 M undefined712,655.96 undefined
2025e85.35 M undefined202,000 undefined-356,327.98 undefined
2024e82.82 M undefined-606,000 undefined-890,820 undefined
202377.06 M undefined-2.99 M undefined-1.87 M undefined
202268.94 M undefined-12.11 M undefined-27.09 M undefined
202128.42 M undefined-3.07 M undefined-3.67 M undefined
202019.67 M undefined1.97 M undefined1.45 M undefined
201919.93 M undefined2.45 M undefined742,000 undefined
201820.41 M undefined2.63 M undefined828,000 undefined
201719.19 M undefined141,000 undefined-323,000 undefined
201616.29 M undefined780,000 undefined408,000 undefined
201514.17 M undefined-1.5 M undefined1.98 M undefined
201413.79 M undefined1.69 M undefined1.1 M undefined
201313.55 M undefined1.47 M undefined840,000 undefined
201213.6 M undefined-740,000 undefined-580,000 undefined
201116 M undefined-340,000 undefined1.26 M undefined
201016.96 M undefined740,000 undefined480,000 undefined
200915.1 M undefined160,000 undefined600,000 undefined
200814.96 M undefined-2.27 M undefined-1.71 M undefined
200715.43 M undefined-830,000 undefined-1.19 M undefined
200611.56 M undefined500,000 undefined-2.87 M undefined
200510.23 M undefined1.19 M undefined-1.92 M undefined

Vita 34 Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (k)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e
10111514151616131313141619201919286877828587128
-10.0036.36-6.677.146.67--18.75--7.6914.2918.755.26-5.00-47.37142.8613.246.493.662.3547.13
60.0063.6466.6764.2966.6762.5056.2561.5461.5453.8542.8650.0052.6355.0057.8957.8942.8625.0036.3634.1532.9432.1821.88
671091010988768101111111217280000
-1,000-2,000-1,000-1,000001,000001,0001,00000001,000-3,000-27,000-1,0000000
-100.00-50.00--------------400.00800.00-96.30----
1.842.12.572.722.722.722.722.923.113.113.043.053.554.084.14.15.8315.8315.880000
-----------------------
Details

Keystats

Revenue and Growth

The Vita 34 Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vita 34 is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2005200620072008200920102011201220132014201520162017201820192020202120222023
                                     
5.654.3510.957.258.065.193.033.792.933.732.623.454.187.099.2110.5235.3718.2319.03
0.760.951.251.62.332.912.752.672.763.883.753.583.712.742.882.4214.9215.4516.88
0.810.81.221.120.831.421.351.382.12.050.370.221.320.850.220.761.041.841.52
0.470.610.570.580.550.630.550.630.550.30.420.290.440.460.290.373.33.893.41
11.151.071.070.70.480-0.29000.140.200.260.310.451.041.651.52
8.697.8615.0611.6212.4710.637.688.188.349.967.317.749.6411.412.9214.5255.6841.0642.36
1.922.182.623.053.323.774.164.544.764.595.155.036.646.919.198.9131.8735.8337.46
000.210.030.160000000.270.13000.341.431.461.66
0.550.61.4621.811.741.671.431.181.100.891.11.090.631.251.663.679.38
0.440.530.740.930.87.036.667.487.186.6812.4711.6821.5419.9916.1614.2322.8318.6517.29
14.9411.9111.9111.9111.9113.4113.4113.9413.9413.9413.7313.4118.3218.3218.3218.3253.6539.4938.11
0.532.730.260.770.70.131.171.050.250.794.184.414.431.611.551.110.8211.3512.11
18.3817.9517.218.6918.726.0827.0728.4427.3127.135.5335.6852.1647.9245.8644.15122.27110.44116
27.0725.8132.2630.3131.1736.7134.7536.6235.6537.0642.8343.4261.859.3258.7858.67177.95151.51158.36
                                     
2.052.052.652.652.652.652.653.033.033.033.033.034.154.154.154.1516.0416.0417.64
15.6315.6323.1223.1923.2423.2423.2423.9523.9518.2118.2118.2123.9123.9124.0124.0136.9636.9642.35
-2.04-4.74-6.03-7.73-7.01-6.97-5.71-6.29-5.451.272.772.751.691.70.16-1.65-7.11-33.68-33.62
00000000000-0-0000000
0000000000000000000
15.6412.9419.7418.1118.8818.9220.1820.6921.5322.5124.0123.9929.7529.7628.3226.5145.8919.3126.37
1.280.780.881.090.810.890.61.171.130.71.321.160.951.111.271.328.258.069.89
000000000000000003.440
1.222.52.22.412.564.52.212.662.693.063.123.466.14.495.024.7542.4844.3438.49
0000000000000000000
0.130.210.210.130.132.061.371.790.140.090.610.61.152.312.132.0512.6516.147.81
2.633.493.293.633.57.454.185.623.963.845.065.228.27.98.428.1263.3871.9756.18
1.891.751.631.51.381.761.811.291.151.13.122.488.035.385.163.2519.7912.0613.77
000000.95000.030.461.71.673.884.314.413.755.715.133.79
6.927.637.617.097.47.718.749.239.29.4910.1510.4112.1612.1812.7517.3247.1249.9561.84
8.819.389.248.598.7810.4210.5510.5210.3811.0614.9714.5524.0721.8722.3124.3372.6367.1379.4
11.4412.8712.5312.2212.2817.8714.7316.1414.3414.920.0319.7732.2729.7730.7332.44136.01139.1135.58
27.0825.8132.2730.3331.1636.7934.9136.8335.8737.444.0443.7662.0259.5359.0458.95181.89158.41161.96
Details

Balance Sheet

Understanding the Balance Sheet

The balance sheet of Vita 34 provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vita 34's financial health and stability.

Assets

Vita 34's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vita 34 must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vita 34 after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vita 34's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (k)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200520062007200820092010201120122013201420152016201720182019202020212022
10-2-2000011100131-3-28
000000011121122238
000000000000000000
000000-110-110000-120
-2-100000000-300000016
000000000000000001,000
0000000000000001,0001,0001,000
-10-1-21002112214632-4
00-1-100-1000-300000-2-6
0-300-1-40000-40-130-1024-5
0-2110-3100000-12100270
000000000000000000
0000000-1-10006-1-2-21-8
3080000000006000-10
30800100-100012-2-2-1-4-6
0000000000000000-42
000000000000000000
1-37-20-20000-10122122-17
-1.83-1.32-2.99-4.010.42-0.01-1.691.251.020.62-1.071.830.753.785.472.890.47-10.92
000000000000000000

Vita 34 stock margins

The Vita 34 margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vita 34. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vita 34.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vita 34's sales revenue. A higher gross margin percentage indicates that the Vita 34 retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vita 34's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vita 34's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vita 34's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vita 34. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vita 34's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vita 34 Margin History

Vita 34 Gross marginVita 34 Profit marginVita 34 EBIT marginVita 34 Profit margin
2027e36.82 %0.72 %0 %
2026e36.82 %1.95 %0.81 %
2025e36.82 %0.24 %-0.42 %
2024e36.82 %-0.73 %-1.08 %
202336.82 %-3.88 %-2.42 %
202225.97 %-17.57 %-39.29 %
202143.77 %-10.81 %-12.9 %
202057.22 %10.03 %7.37 %
201959.11 %12.31 %3.72 %
201858.67 %12.89 %4.06 %
201756.28 %0.73 %-1.68 %
201652.92 %4.79 %2.5 %
201545.79 %-10.57 %13.97 %
201457.12 %12.26 %7.98 %
201359.48 %10.85 %6.2 %
201259.12 %-5.44 %-4.26 %
201159.13 %-2.13 %7.88 %
201063.8 %4.36 %2.83 %
200967.15 %1.06 %3.97 %
200865.57 %-15.17 %-11.43 %
200767.34 %-5.38 %-7.71 %
200668.34 %4.33 %-24.83 %
200566.76 %11.63 %-18.77 %

Vita 34 Stock Sales Revenue, EBIT, Earnings per Share

The Vita 34 earnings per share therefore indicates how much revenue Vita 34 has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Vita 34 earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vita 34's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vita 34’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vita 34's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vita 34 Revenue, EBIT and net profit per share

DateVita 34 Sales per ShareVita 34 EBIT per shareVita 34 Earnings per Share
2027e7.26 undefined0 undefined0 undefined
2026e4.98 undefined0 undefined0.04 undefined
2025e4.84 undefined0 undefined-0.02 undefined
2024e4.7 undefined0 undefined-0.05 undefined
20234.85 undefined-0.19 undefined-0.12 undefined
20224.36 undefined-0.77 undefined-1.71 undefined
20214.88 undefined-0.53 undefined-0.63 undefined
20204.8 undefined0.48 undefined0.35 undefined
20194.86 undefined0.6 undefined0.18 undefined
20185 undefined0.64 undefined0.2 undefined
20175.41 undefined0.04 undefined-0.09 undefined
20165.34 undefined0.26 undefined0.13 undefined
20154.66 undefined-0.49 undefined0.65 undefined
20144.43 undefined0.54 undefined0.35 undefined
20134.36 undefined0.47 undefined0.27 undefined
20124.66 undefined-0.25 undefined-0.2 undefined
20115.88 undefined-0.13 undefined0.46 undefined
20106.24 undefined0.27 undefined0.18 undefined
20095.55 undefined0.06 undefined0.22 undefined
20085.5 undefined-0.83 undefined-0.63 undefined
20076 undefined-0.32 undefined-0.46 undefined
20065.5 undefined0.24 undefined-1.37 undefined
20055.56 undefined0.65 undefined-1.04 undefined

Vita 34 business model

Vita 34 AG is a leading company in the field of stem cell technology. It was founded in Leipzig in 1997 and has since had an impressive history. The company focuses on the storage of stem cells from umbilical cord blood and umbilical cord tissue. These stem cells can be used later in life for the treatment of various diseases. The business model of Vita 34 AG involves customers storing and preserving their stem cells with them. The company offers various options to meet individual needs. Customers can choose between different packages that include different services. For example, a package can be booked that only includes the storage of umbilical cord blood, or another package that also includes the storage of umbilical cord tissue. In addition to stem cell storage, Vita 34 AG also offers various supplementary services. For example, customers can have genetic predisposition tests conducted to determine the risk for certain diseases. This allows customers to take targeted preventive measures and consider alternative treatment options if necessary. Another important aspect of Vita 34 AG's business is the trade of stem cells. By storing umbilical cord blood and tissue, the company builds an extensive portfolio of stem cells that can be sold to medical institutions when needed. The company works closely with doctors and research institutions to use the stem cells efficiently. Vita 34 AG operates not only in German-speaking countries but also has branches in other countries such as Austria, Switzerland, and the Netherlands. This allows the company to operate internationally and cater to the specific needs of individual countries. In addition to the mentioned services, Vita 34 AG also offers various products. For example, there are special storage kits for the storage of umbilical cord blood and tissue. Test kits for genetic predisposition tests can also be purchased. Vita 34 AG aims to increase awareness of stem cells and their therapeutic possibilities. Through intensive marketing, including in social networks, the company strives to ensure that as many people as possible learn about the benefits of stem cell technology and decide to store their stem cells with the company. Vita 34 AG has had an impressive development in recent years. It is now globally known and has established itself as a competent and reliable partner in the field of stem cell technology. With its wide range of services and products, it is often the first choice for many people when it comes to storing stem cells. Vita 34 is one of the most popular companies on Eulerpool.com.

Vita 34 SWOT Analysis

Strengths

Vita 34 AG is a leading company in the field of stem cell storage and regenerative medicine. It has a strong reputation and brand recognition, which gives it a competitive edge in the market.

The company has a well-established customer base and a wide network of partner hospitals and clinics.

Vita 34 AG possesses advanced technology and expertise in stem cell processing and cryopreservation, ensuring high-quality and reliable services.

Weaknesses

One of the weaknesses of Vita 34 AG is its dependency on regulatory approvals and governmental policies, which can impact its operations and market potential.

The company may face challenges related to customer education and awareness regarding the benefits and applications of stem cell storage.

Vita 34 AG's geographical presence is mainly concentrated in specific regions, limiting its market reach and growth opportunities.

Opportunities

The increasing acceptance of stem cell therapies and regenerative medicine presents an opportunity for Vita 34 AG to expand its services and customer base.

Collaboration with research institutions and healthcare providers can lead to the development of new treatments and further advancements in the field, benefiting Vita 34 AG.

International expansion and entering emerging markets with growing healthcare infrastructure can provide significant growth prospects for the company.

Threats

Competition from other stem cell banks and companies offering similar services is a major threat to Vita 34 AG's market share and profitability.

Changes in healthcare regulations and reimbursement policies can impact the demand for stem cell storage and affect the company's revenue streams.

Ethical and legal concerns surrounding stem cell research and usage may impose restrictions and limitations on Vita 34 AG's operations.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vita 34 Eulerpool Fair Value

Details

Fair Value

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vita 34 historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vita 34 shares outstanding

The number of shares was Vita 34 in 2024 — This indicates how many shares 15.881 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

Revenue Per Share

Revenue per share represents the total revenue Vita 34 earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vita 34's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vita 34’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vita 34's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vita 34 dividend history and estimates

In 2024, Vita 34 paid a dividend amounting to 0 EUR. Dividend means that Vita 34 distributes a portion of its profits to its owners.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

Dividend Overview

The dividend per year chart for Vita 34 provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Vita 34’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Vita 34's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Vita 34 Dividend History

DateVita 34 Dividend
2026e0.04 undefined
2025e-0.02 undefined
2024e-0.05 undefined
20190.16 undefined
20180.16 undefined
20170.16 undefined
20160.16 undefined
20150.15 undefined

Vita 34 dividend payout ratio

In 2024, Vita 34 had a payout ratio of 89.31%. The payout ratio indicates the percentage of the company's profits that Vita 34 distributes as dividends.
  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

What is Yearly Payout Ratio?

The yearly payout ratio for Vita 34 represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Vita 34 could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Vita 34's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Vita 34 Payout Ratio History

DateVita 34 Payout ratio
2027e89.76 %
2026e89.97 %
2025e89.99 %
2024e89.31 %
202390.61 %
202290.05 %
202187.27 %
202094.52 %
201988.37 %
201878.92 %
2017-170.96 %
2016116.26 %
201522.4 %
201494.52 %
201394.52 %
201294.52 %
201194.52 %
201094.52 %
200994.52 %
200894.52 %
200794.52 %
200694.52 %
200594.52 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Vita 34.

Vita 34 latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2007-0.02 -0.05  (-162.91 %)2007 Q3
1

Vita 34 shareholders

%
Name
Stocks
Change
Date
58.44700 % Schuhbauer (Florian)10,310,051010/1/2024
5.40003 % Shareholder Value Beteiligungen AG952,56606/30/2024
4.60003 % Management of VITA 34 AG811,44506/30/2024
2.03015 % ESALIENS TFI SA358,1194,00012/31/2023
0.48403 % Bellevue Asset Management AG85,38377,1836/30/2023
0.09070 % GVC Gaesco Gesti¿n SGIIC S.A.16,00006/30/2024
0.04932 % Societas Vermögensverwaltung GmbH8,70009/30/2024
0.00611 % Gutmann Finanz Strategien AG1,07703/31/2024
0 % Signal Iduna Asset Management GmbH0-2,0009/30/2024
0 % Invesco Advisers, Inc.0-296,9869/30/2023
1

Vita 34 Executives and Management Board

Dr. Wolfgang Knirsch

(62)
Vita 34 Chairman of the Management Board, Chief Executive Officer
Compensation 292,100

Mr. Andreas Schafhirt

(60)
Vita 34 Chief Financial Officer, Member of the Management Board
Compensation 95,376

Mr. Florian Schuhbauer

(47)
Vita 34 Independent Deputy Chairman of the Supervisory Board (since 2020)
Compensation 49,180

Mr. Andreas Fuechsel

Vita 34 Independent Member of the Supervisory Board
Compensation 20,000

Mr. Frank Koehler

(58)
Vita 34 Independent Member of the Supervisory Board (since 2017)
Compensation 20,000
1
2

Most common questions regarding Vita 34

What values and corporate philosophy does Vita 34 represent?

Vita 34 AG is a leading biotech company that specializes in stem cell banking. The company's corporate philosophy is based on three core values: responsibility, innovation, and quality. Vita 34 AG is committed to taking responsibility for the long-term health preservation of individuals and their families by offering secure and reliable stem cell storage solutions. Through constant innovation, the company strives to stay at the forefront of stem cell technologies, ensuring the highest standards of quality and safety. Vita 34 AG believes in the immense potential of stem cells and their ability to revolutionize medical treatments, making them a trusted and forward-thinking partner in the field of regenerative medicine.

In which countries and regions is Vita 34 primarily present?

Vita 34 AG is primarily present in Germany, Austria, Switzerland, and other European countries.

What significant milestones has the company Vita 34 achieved?

Vita 34 AG has achieved significant milestones in its history. It is noteworthy that the company pioneered the storage of umbilical cord blood as regenerative medicine in Europe. With over 20 years of experience, Vita 34 has established itself as a leading provider of stem cell banking services, offering secure and reliable storage options for families. The company has successfully expanded its operation to various countries, including Austria, Switzerland, and Brazil. Vita 34 AG continues to invest in research and development, ensuring cutting-edge technologies and future advancements in the field of stem cell preservation.

What is the history and background of the company Vita 34?

Vita 34 AG is a German company that specializes in the field of stem cell banking. Established in 1997, Vita 34 is one of the oldest and largest stem cell banks in Europe. The company provides individuals the opportunity to store stem cells from umbilical cord blood and tissue which can be used in potential future medical treatments. Vita 34 AG's vision has always been to contribute to the development of innovative medical therapies and improve the quality of life for patients. With a strong focus on research and technological advancements, Vita 34 AG continues to be a leading player in the stem cell industry.

Who are the main competitors of Vita 34 in the market?

The main competitors of Vita 34 AG in the market include Cryo-Save AG, Cryo-Vita GmbH, StemCyte Inc., LifeCell International Pvt. Ltd, and Cordlife Group Limited.

In which industries is Vita 34 primarily active?

Vita 34 AG is primarily active in the biotechnology and healthcare industries.

What is the business model of Vita 34?

Vita 34 AG's business model focuses on stem cell banking and regenerative medicine. As a biotechnology company, Vita 34 AG specializes in the collection, processing, and storage of stem cells derived from umbilical cord blood. By offering parents the opportunity to preserve their newborn's cord blood, Vita 34 AG contributes to potential future medical treatments and therapies. Through extensive quality control and state-of-the-art technologies, Vita 34 AG ensures the safe and professional handling of stem cells. With a strong emphasis on research and development, Vita 34 AG continues to advance its expertise in regenerative medicine, aiming to harness the potential of stem cells for various health-related applications.

What is the P/E ratio of Vita 34 2025?

The Vita 34 P/E ratio is -185.4.

What is the P/S ratio of Vita 34 2025?

The Vita 34 P/S ratio is 0.77.

What is the Quality Investing of Vita 34?

The Quality Investing for Vita 34 is 3/10.

What is the revenue of Vita 34 2025?

The expected Vita 34 revenue is 85.35 M EUR.

How high is the profit of Vita 34 2025?

The expected Vita 34 profit is -356,327.98 EUR.

What is the business model of Vita 34

The Vita 34 AG is a leading company in the field of stem cell storage for medical purposes. The company's business model includes various divisions to provide its customers with tailored solutions for stem cell storage. The main division of Vita 34 is the storage of stem cells for newborns. In this case, the company extracts valuable stem cells from the umbilical cord of the newborn during umbilical cord blood donation and stores them properly in a specially developed cryogenic storage system. These stem cells can be used later for the treatment of life-threatening diseases. Vita 34 also offers a storage solution for adults. With peripheral stem cell storage, stem cells can be taken from an adult's blood and stored. These stem cells can be effectively used for the treatment of diseases such as cancer and autoimmune diseases. Another division of the company is the sale of stem cell products. Vita 34 offers various products derived from the body's own stem cell material. This includes, among other things, the VitaPlus umbilical cord blood serum as a cosmetic product for skincare and the VitaMine&More dietary supplement. Both products contain important components from stem cells that support the body's immune system and promote well-being. In addition, Vita 34 offers a comprehensive service platform that supports customers with all questions related to stem cell therapy. This includes, among other things, consultations with medical experts and support in finding suitable therapy centers and methods. The business model of Vita 34 AG is strongly focused on customer orientation. The company offers its customers tailored solutions for stem cell storage as well as comprehensive consulting and service. This makes the company a worldwide leading provider of stem cell-based solutions for medical purposes.

What is the Vita 34 dividend?

Vita 34 pays a dividend of 0 EUR distributed over payouts per year.

How often does Vita 34 pay dividends?

The dividend cannot currently be calculated for Vita 34 or the company does not pay out a dividend.

What is the Vita 34 ISIN?

The ISIN of Vita 34 is DE000A0BL849.

What is the Vita 34 WKN?

The WKN of Vita 34 is A0BL84.

What is the Vita 34 ticker?

The ticker of Vita 34 is V3V.DE.

How much dividend does Vita 34 pay?

Over the past 12 months, Vita 34 paid a dividend of 0.16 EUR . This corresponds to a dividend yield of about 3.85 %. For the coming 12 months, Vita 34 is expected to pay a dividend of 0.04 EUR.

What is the dividend yield of Vita 34?

The current dividend yield of Vita 34 is 3.85 %.

When does Vita 34 pay dividends?

Vita 34 pays a quarterly dividend. This is distributed in the months of September, July, June, July.

How secure is the dividend of Vita 34?

Vita 34 paid dividends every year for the past 0 years.

What is the dividend of Vita 34?

For the upcoming 12 months, dividends amounting to 0.04 EUR are expected. This corresponds to a dividend yield of 0.87 %.

In which sector is Vita 34 located?

Vita 34 is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vita 34 kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vita 34 from 6/7/2019 amounting to 0.16 EUR, you needed to have the stock in your portfolio before the ex-date on 6/5/2019.

When did Vita 34 pay the last dividend?

The last dividend was paid out on 6/7/2019.

What was the dividend of Vita 34 in the year 2024?

In the year 2024, Vita 34 distributed 0 EUR as dividends.

In which currency does Vita 34 pay out the dividend?

The dividends of Vita 34 are distributed in EUR.

All fundamentals about Vita 34

Our stock analysis for Vita 34 Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vita 34 Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.